10-(3-chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4(3H,10H)-dione | 317326-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 10-(3-chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4(3H,10H)-dione
• 英文别名: HLI98c；10-(3-Chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4-dione
• CAS: 317326-90-2
• 化学式: C₁₇H₉ClN₄O₄
• 分子量: 368.736
• InChiKey: BRCGPVHRBGGGPW-UHFFFAOYSA-N

物化性质

• 熔点：
  368-369 °C(Solv: water (7732-18-5))
• 密度：
  1.66±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  10-(3-chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4(3H,10H)-dione 在 劳森试剂 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以37%的产率得到10-(3-chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4(3H,10H)-dithione
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Pyrimido[4,5-b]quinoline-2,4- dione Derivatives as MDM2 Ubiquitin Ligase Inhibitors

  摘要：

  合成了一系列嘧啶并[4,5-b]喹啉-2,4-二酮衍生物，并在体外评估了它们对五种人类癌细胞株的细胞毒活性。对所选化合物的 MDM2 E3 连接酶抑制活性和 p53-MDM2 结合抑制活性进行了测试。在测试的化合物中，与 HLI98c 相比，四个含硫化合物（4-7）显示出更强的细胞毒性活性和更好的 MDM2 E3 连接酶抑制活性。三个化合物（4-6）显示出更好的 p53-MDM2 结合抑制效力，其 IC50 值从 1.3 μM 到 9.0 μM。

  DOI：

  10.2174/1573406411309040012
• 作为产物：
  描述：

  6-(3-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione 、 2-氯-5-硝基苯甲醛 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以26%的产率得到10-(3-chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4(3H,10H)-dione
  参考文献：
  名称：

  Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells

  摘要：

  A family of 5-deazaflavin derivatives has been synthesised using a two-step convergent strategy. The biological activity of these compounds was evaluated in cells, by assessing their ability to stabilize and activate p53. These compounds may act as low molecular weight inhibitors of the E3 activity of HMD2 in tumours that retain wild-type p53. Importantly, we have demonstrated that the nitro group present in all three of the original lead compounds [1-3 (HL198C-E)] is not essential for observation of this biological activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.011

文献信息

• Deazaflavin compounds and methods of use thereof
  申请人：Weissman M. Allan

  公开号：US20060211718A1

  公开（公告）日：2006-09-21

  The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.

  本发明的特征是5-去氮黄素化合物、5-去氮黄素化合物的药物组合物和治疗癌症患者的方法，该方法包括给患者服用一种或多种本发明的5-去氮黄素化合物。
• DEAZAFLAVIN COMPOUNDS AND METHODS OF USE THEREOF
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP1633749A2

  公开（公告）日：2006-03-15
• Inhibitors of ubiquitin E1
  申请人：Weissman Allan M.

  公开号：US20080306130A1

  公开（公告）日：2008-12-11

  The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.
• HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Weissman Allan

  公开号：US20100056549A1

  公开（公告）日：2010-03-04

  The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.
• INHIBITORS OF UBIQUITIN E1
  申请人：Weissman Allan M.

  公开号：US20100305180A1

  公开（公告）日：2010-12-02

  The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.